This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cardiovascular disease				
Restenosis	Pyruvate dehydrogenase kinase 2 (PDK2)	Rodent, rabbit and porcine studies suggest inhibiting PDK2 in coronary artery transplants could prevent restenosis. In rodent and rabbit models of injury-induced arterial restenosis, shRNA against *PDK2* or the PDK2 inhibitor dichloroacetate (DCA) decreased markers of restenosis such as myointimal proliferation compared with control shRNA or vehicle. In a swine model of coronary artery restenosis, DCA decreased graft restenosis compared with vehicle. Next steps include investigating DCA's long-term safety and defining a patient population most likely to benefit from the molecule.	Patent application filed; licensing details available from Stanford University's Office of Technology Licensing	Deuse, T. *et al. Nature*; published online April 20, 2014; doi:10.1038/nature13232 **Contact:** Sonja Schrepfer, Stanford University, Stanford, Calif. e-mail: schrepfer@stanford.edu

SciBX 7(20); doi:10.1038/scibx.2014.579
Published online May 22, 2014